These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28083256)

  • 1. Assessment of the implementation of the EU Drugs Strategy 2005-2012 and its Action Plans.
    Culley DM; Taylor J; Rubin J; Hoorens S; Disley E; Rabinovich L
    Rand Health Q; 2012; 2(2):15. PubMed ID: 28083256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Governance in EU illicit drugs policy.
    Edwards C; Galla M
    Int J Drug Policy; 2014 Sep; 25(5):942-7. PubMed ID: 25060612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid-Term Assessment of the EU Drugs Strategy 2013-2020 and Final Evaluation of the Action Plan on Drugs 2013-2016: Final report.
    Emilie B; Matthew D; Emma D; Cristina Gonzalez M; Stephen H; Stijn H; Kristy K; Martin S; Jirka T
    Rand Health Q; 2018 Jan; 7(2):4. PubMed ID: 29416944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tackling rare diseases at European level: why do we need a harmonized framework?
    Taruscio D; Trama A; Stefanov R
    Folia Med (Plovdiv); 2007; 49(1-2):59-67. PubMed ID: 18018471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A review of the nutritional management plans in the member states of the European Union].
    Lachat C; Dehenauw S; van Camp J; Matthys C; Larondelle Y; Kolsteren P
    Verh K Acad Geneeskd Belg; 2006; 68(1):55-76. PubMed ID: 16610423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Falsification of medical products: criminal law mechanism combating threats to public health.
    Gutorova N; Zhytnyi O; Soloviov O
    Wiad Lek; 2019; 72(5 cz 1):856-861. PubMed ID: 31175785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transposition and implementation of EU rare disease policy in Eastern Europe.
    Pejcic AV; Iskrov G; Raycheva R; Stefanov R; Jakovljevic MM
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):557-566. PubMed ID: 28975845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National plans and strategies on rare diseases in Europe.
    Taruscio D; Vittozzi L; Stefanov R
    Adv Exp Med Biol; 2010; 686():475-91. PubMed ID: 20824461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.
    Fears R; Kaufmann S; Ter Meulen V; Zumla A;
    Tuberculosis (Edinb); 2010 May; 90(3):182-7. PubMed ID: 20382566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A concise overview of national nutrition action plans in the European Union Member States.
    Lachat C; Van Camp J; De Henauw S; Matthys C; Larondelle Y; Remaut-De Winter AM; Kolsteren P
    Public Health Nutr; 2005 May; 8(3):266-74. PubMed ID: 15918923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plus ça change, plus c'est la même chose: a Review of Recent Alcohol Policy Developments in Europe.
    Rice P
    Alcohol Alcohol; 2019 Mar; 54(2):123-127. PubMed ID: 30801630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing and using quality measures for children's health care: perspectives on the state of the practice.
    Shaller D
    Pediatrics; 2004 Jan; 113(1 Pt 2):217-27. PubMed ID: 14702504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rethinking 'flexibilities' in the international drug control system-Potential, precedents and models for reforms.
    Collins J
    Int J Drug Policy; 2018 Oct; 60():107-114. PubMed ID: 28129946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping novel psychoactive substances policy in the EU: The case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden.
    Neicun J; Steenhuizen M; van Kessel R; Yang JC; Negri A; Czabanowska K; Corazza O; Roman-Urrestarazu A
    PLoS One; 2019; 14(6):e0218011. PubMed ID: 31242225
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.